Literature DB >> 17971582

Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients.

Michael K M Kam1, Sing-Fai Leung, Benny Zee, Ricky M C Chau, Joyce J S Suen, Frankie Mo, Maria Lai, Rosalie Ho, Kin-yin Cheung, Brian K H Yu, Samuel K W Chiu, Peter H K Choi, Peter M L Teo, Wing-hong Kwan, Anthony T C Chan.   

Abstract

PURPOSE: This randomized trial compared the rates of delayed xerostomia between two-dimensional radiation therapy (2DRT) and intensity-modulated radiation therapy (IMRT) in the treatment of early-stage nasopharyngeal carcinoma (NPC). PATIENTS AND METHODS: Between November 2001 and December 2003, 60 patients with T1-2bN0-1M0 NPC were randomly assigned to receive either IMRT or 2DRT. Primary end point was incidence of observer-rated severe xerostomia at 1 year after treatment based on Radiotherapy Oncology Group /European Organisation for the Research and Treatment of Cancer late radiation morbidity scoring criteria. Parallel assessment with patient-reported outcome, stimulated parotid flow rate (SPFR), and stimulated whole saliva flow rate (SWSFR) were also made.
RESULTS: At 1 year after treatment, patients in IMRT arm had lower incidence of observer-rated severe xerostomia than patients in the 2DRT arm (39.3% v 82.1%; P = .001), parallel with a higher fractional SPFR (0.90 v 0.05; P < .0001), and higher fractional SWSFR (0.41 v 0.20; P = .001). As for patient's subjective feeling, although a trend of improvement in patient-reported outcome was observed after IMRT, recovery was incomplete and there was no significant difference in patient-reported outcome between the two arms.
CONCLUSION: IMRT is superior to 2DRT in preserving parotid function and results in less severe delayed xerostomia in the treatment of early-stage NPC. Incomplete improvement in patient's subjective xerostomia with parotid-sparing IMRT reflects the need to enhance protection of other salivary glands.

Entities:  

Mesh:

Year:  2007        PMID: 17971582     DOI: 10.1200/JCO.2007.11.5501

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  188 in total

1.  Intensity-modulated radiotherapy for nasopharyngeal carcinoma: improvement of the therapeutic ratio with helical tomotherapy vs segmental multileaf collimator-based techniques.

Authors:  A M Chen; C C Yang; J Marsano; T Liu; J A Purdy
Journal:  Br J Radiol       Date:  2012-01-17       Impact factor: 3.039

2.  Unilateral neck therapy in the human papillomavirus ERA: accepted regional spread patterns.

Authors:  Thomas J Galloway; Miriam N Lango; Barbara Burtness; Ranee Mehra; Karen Ruth; John A Ridge
Journal:  Head Neck       Date:  2012-02-02       Impact factor: 3.147

3.  Systemic chemotherapy followed by locoregional definitive intensity-modulated radiation therapy yields prolonged survival in nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis.

Authors:  Shao-xuan Hu; Xiao-hui He; Mei Dong; Bo Jia; Sheng-yu Zhou; Jian-liang Yang; Sheng Yang; Chang-Gong Zhang; Peng Liu; Yan Qin; Lin Gui
Journal:  Med Oncol       Date:  2015-07-29       Impact factor: 3.064

4.  A split-parotid delineation approach for dose optimization in volumetric modulated arc therapy for nasopharyngeal carcinoma patients with parapharyngeal space invasion and level IIa cervical lymph node involvements.

Authors:  Wei Xiao; Zhixiong Lin; Wuzhe Zhang; Mei Li; Vincent W C Wu
Journal:  Br J Radiol       Date:  2016-02-03       Impact factor: 3.039

Review 5.  A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact.

Authors:  S B Jensen; A M L Pedersen; A Vissink; E Andersen; C G Brown; A N Davies; J Dutilh; J S Fulton; L Jankovic; N N F Lopes; A L S Mello; L V Muniz; C A Murdoch-Kinch; R G Nair; J J Napeñas; A Nogueira-Rodrigues; D Saunders; B Stirling; I von Bültzingslöwen; D S Weikel; L S Elting; F K L Spijkervet; M T Brennan
Journal:  Support Care Cancer       Date:  2010-03-25       Impact factor: 3.603

6.  Organ sparing and clinical outcome with step-and-shoot IMRT for head and neck cancer: a mono-institutional experience.

Authors:  Rosario Mazzola; Giuseppe Ferrera; Filippo Alongi; Mariella Mannino; Boris Abbate; Teresa Cucchiara; Giuseppina Iacoviello; Francesco Sciumè; Gioacchino Di Paola; Manuela Federico; Livio Blasi; Antonio Lo Casto; Roberto Lagalla; Domenico Messana
Journal:  Radiol Med       Date:  2015-02-07       Impact factor: 3.469

7.  Alternative endpoints to the 5-year overall survival and locoregional control for nasopharyngeal carcinoma: A retrospective analysis of 2,450 patients.

Authors:  Chen Chen; Wei Yi; Jin Gao; Xiao-Hui Li; Lu-Jun Shen; Bo-Fei Li; Zi-Wei Tu; Ya-Lan Tao; Chang-Bin Jiang; Yun-Fei Xia
Journal:  Mol Clin Oncol       Date:  2014-02-20

8.  Error in the parotid contour delineated using computed tomography images rather than magnetic resonance images during radiotherapy planning for nasopharyngeal carcinoma.

Authors:  Chengxin Liu; Xudong Kong; Guanzhong Gong; Tonghai Liu; Baosheng Li; Yong Yin
Journal:  Jpn J Radiol       Date:  2014-02-21       Impact factor: 2.374

9.  Institutional clinical trial accrual volume and survival of patients with head and neck cancer.

Authors:  Evan J Wuthrick; Qiang Zhang; Mitchell Machtay; David I Rosenthal; Phuc Felix Nguyen-Tan; André Fortin; Craig L Silverman; Adam Raben; Harold E Kim; Eric M Horwitz; Nancy E Read; Jonathan Harris; Qian Wu; Quynh-Thu Le; Maura L Gillison
Journal:  J Clin Oncol       Date:  2014-12-08       Impact factor: 44.544

10.  Recurrent oropharyngeal cancer after organ preserving treatment: pattern of failure and survival.

Authors:  M de Ridder; Z A R Gouw; J J Sonke; A Navran; B Jasperse; J Heukelom; M E T Tesselaar; W M C Klop; M W M van den Brekel; Abrahim Al-Mamgani
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-09       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.